West, who has been president of Hologic’s diagnostics solutions division since October 2014, is a Johnson & Johnson (NYSE:JNJ) veteran, Menlo Park, Calif.-based Intersect ENT said. The company in May tapped lead director Kieran Gallahue to be interim CEO after Lisa Earnhardt stepped away to become head of medical devices for Abbott (NYSE:ABT).
“Tom is a proven healthcare leader bringing more than two decades of medical technology experience to Intersect ENT. We look forward to leveraging his deep knowledge of and expertise in accelerating growth through commercial execution, product innovation and the building of strong, integrated teams,” Gallahue said in prepared remarks. “The board and I are impressed with Tom’s strategic insights and established track record of strong execution and successful product commercialization. We believe Tom’s leadership will be a great benefit to us as we continue to advance our products in the marketplace, drive growth across our portfolio and deliver on our goal of making localized drug delivery the standard of care for patients suffering from chronic sinusitis.”
“I’m thrilled to join Intersect ENT at this time and look forward to building on the company’s history of innovation to drive accelerated growth via strong execution and with consistent financial and operational performance,” West added. “I am excited to join the Intersect ENT team in our mission of transforming care in the ear, nose & throat specialty and extend the company’s leadership in innovation in localized drug delivery. With focused execution across both Intersect ENT’s commercialized products and pipeline of innovative, clinically meaningful therapies, I am confident that we can build an even stronger foundation for future growth as we enhance value to our shareholders.”
Intersect ENT also said that it’s begun a search to replace CFO Jeri Hilleman, who’s is slated to step down at the beginning of next year to focus on “board responsibilities.”
“We want to express our deep appreciation for Jeri’s many and significant accomplishments over the years, and are deeply grateful for her commitment to ensure a seamless transition throughout this planned process,” Gallahue said. “Jeri has contributed broadly to the organization over the years, and we wish her well in the next stage of her career.”
Wayne, Pa.-based Globus promoted CFO Dan Scavilla to chief commercial officer last August, saying he’d keep the finance chief role until a replacement was found.
“We are delighted to have Keith join our senior team. He’s an accomplished executive with strong track record of sound financial leadership, bringing efficiency to operations and corporate value creation,” president & CEO Dave Demski said in prepared remarks. “We believe Keith will be a valuable addition to our executive management team and will help support our growth as Globus Medical becomes a larger player in the musculoskeletal market.”
Apollo Endosurgery founder McWilliams joins Santé Ventures
VC shop Santé Ventures said it named Dennis McWilliams, the former founder, CEO and CCO at Apollo Endosurgery (NSDQ:APEN), as a venture partner.
“Dennis has a proven track record for bringing creativity, energy and intellect to the process of building new ventures in life sciences,” Santé co-founder & managing director Kevin Lalande said in prepared remarks. “We welcome Dennis to the team and in addition to benefitting from his experience and insights, we are confident he can help us leverage our deep network of relationships in identifying and expanding opportunities within our investment focus. Dennis will fit well into our collaborative culture and we are excited to partner with him to advance new products and services to better serve patients.”
“We welcome Dr. Gottlieb to Pfizer’s board of directors,” CEO Albert Bourla said in prepared remarks. “Through his work as a physician and his time at the FDA, Scott has continually demonstrated an understanding of both patients’ needs and the rapidly changing dynamics of biopharmaceutical research and development.”
“Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives,” added chairman Ian Read.